tbuckley/cabot-search huggingface dataset:
Evaluation of Flow After Transcatheter Aortic Valve Replacement in Patients With Low-Flow Aortic Stenosis
Authors: Venkatesh Y. Anjan, Howard C. Herrmann, Philippe Pibarot, William J. Stewart, Samir Kapadia, E. Murat Tuzcu, Vasilis Babaliaros, Vinod H. Thourani, Wilson Y. Szeto, Joseph E. Bavaria, Susheel Kodali, Rebecca T. Hahn, Mathew Williams, D. Craig Miller, Pamela S. Douglas, Martin B. Leon
Journal: JAMA Cardiology (2016)

Low-flow (LF) severe aortic stenosis (AS) is an independent predictor of mortality in patients undergoing aortic valve replacement (AVR). Little is known about improvement in flow after AVR and its effects on survival.To determine whether higher flow (left-ventricular stroke volume index [LVSVI]) after transcatheter AVR (TAVR) would indicate better clinical outcomes in this at-risk population.A substudy analysis of data from the Placement of Aortic Transcatheter Valves (PARTNER) randomized clinical trial and continued-access registry was conducted. A total of 984 participants with evaluable echocardiograms and baseline LF AS (LVSVI ≤35 mL/m2) were included. The trial was conducted at 26 sites in the United States and Canada. Patients were stratified after TAVR into tertiles by discharge LVSVI status (severe low flow [SLF], moderate low flow [MLF], and normal flow [(NF]). The present study was conducted from May 11, 2007, to January 9, 2012, with data analysis performed from April 25, 2014, to January 21, 2016.The primary end point was all-cause mortality at 1 year.Baseline characteristics of 984 patients with LF AS included mean (SD) age, 84 (7) years; 582 (59.1%) men; mean Society of Thoracic Surgeons (STS) score, 11.4% (4.0%); and mean LVSVI, 27.6 (5.0) mL/m2. The discharge LVSVI values by group were SLF, 23.1 (3.5) mL/m2; MLF, 31.7 (2.2) mL/m2; and NF, 43.1 (7.0). All-cause mortality at 1 year was SLF, 26.5%; MLF, 20.1%; and NF, 19.6% (P = .045). Mean LVSVI normalized by 6 months in the MLF (35.9 [9.3] mL/m2) and NF (38.8 [11.1] mL/m2) groups, but remained low in the SLF group at 6 months and 1 year (31.4 [8.4] and 33.0 [8.3] mL/m2], respectively) (P < .001 for all groups). Reported as multivariate hazard ratio, mortality at 1 year was higher in the SLF group compared with the other groups (1.61; 95% CI, 1.17-2.23; P = .004). In addition to SLF, sex (1.59; 95% CI, 1.18-2.13; P = .002), presence of atrial fibrillation (1.41; 95% CI, 1.06-1.87; P = .02), STS score (1.03; 95% CI, 1.01-1.06; P = .02), presence of moderate or severe mitral regurgitation at discharge (1.65; 95% CI, 1.21-2.26; P = .001), pre-TAVR mean transvalvular gradient (0.98; 95% CI, 0.97-0.99; P = .004), and effective orifice area index (1.87; 95% CI, 1.09-3.19; P = .02) were independent predictors of 1-year mortality.Severe LF at discharge is associated with an increased risk of mortality following TAVR in patients with severe AS and preexisting LF. The identification of remedial causes of persistent LF after TAVR may represent an opportunity to improve the outcome of these patients.clinicaltrials.gov Identifier: NCT00530894.
Tumor necrosis factor: is it a breakthrough?
Authors: F O Stephens
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.688 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636798 Tumor necrosis factor: is it a breakthrough? F O StephensxF O StephensSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.688 PDF "Tumor necrosis factor: is it a breakthrough?." Journal of Clinical Oncology, 14(2), pp. 688–689© 1996 by American Society of Clinical Oncology
HG-20COMBINATION OF EPIGENETIC MODIFIERS CBL0137 AND PANOBINOSTAT IS HIGHLY POTENT IN VITRO AND IN VIVO FOR DIFFUSE INTRINSIC PONTINE GLIOMA
Authors: Anahid Ehteda, Maria Tsoli, Arjanna Chitranjan, Cecilia Chang, Sandy Simon, Anne Kankean, Han Shen, Jie Liu, Michelle Haber, Andrei Gudkov, David Ziegler
Journal: Neuro-Oncology (2016)
Calorie restriction protects against experimental abdominal aortic aneurysms in mice
Authors: Yue Liu, Ting-Ting Wang, Ran Zhang, Wen-Yan Fu, Xu Wang, Fang Wang, Peng Gao, Yang-Nan Ding, Yan Xie, De-Long Hao, Hou-Zao Chen, De-Pei Liu
Journal: The Journal of Experimental Medicine (2016)

Abdominal aortic aneurysm (AAA), characterized by a localized dilation of the abdominal aorta, is a life-threatening vascular pathology. Because of the current lack of effective treatment for AAA rupture, prevention is of prime importance for AAA management. Calorie restriction (CR) is a nonpharmacological intervention that delays the aging process and provides various health benefits. However, whether CR prevents AAA formation remains untested. In this study, we subjected Apoe−/− mice to 12 wk of CR and then examined the incidence of angiotensin II (AngII)–induced AAA formation. We found that CR markedly reduced the incidence of AAA formation and attenuated aortic elastin degradation in Apoe−/− mice. The expression and activity of Sirtuin 1 (SIRT1), a key metabolism/energy sensor, were up-regulated in vascular smooth muscle cells (VSMCs) upon CR. Importantly, the specific ablation of SIRT1 in smooth muscle cells abolished the preventive effect of CR on AAA formation in Apoe−/− mice. Mechanistically, VSMC-SIRT1–dependent deacetylation of histone H3 lysine 9 on the matrix metallopeptidase 2 (Mmp2) promoter was required for CR-mediated suppression of AngII-induced MMP2 expression. Together, our findings suggest that CR may be an effective intervention that protects against AAA formation.
Not so fast, and not so easy: Essentialism doesn't emerge from a simple heuristic
Authors: Nick Braisby
Journal: Behavioral and Brain Sciences (2014)

Abstract Cimpian &amp; Salomon's (C&amp;S's) proposal comes unstuck on precisely the claim that inherence is an heuristic, able to deliver simple, shallow outputs that are right most of the time. Instead, the inherence heuristic delivers outputs that imply it is not an heuristic after all, and is simply too fast and too easy a mechanism to do the job of explaining categorisations.
The Growth of Normal Plant Tissue &lt;italic&gt;in vitro&lt;/italic&gt; as Affected by Chemical Carcinogens and Plant Growth Substances. II. the Cytology of the Carrot-Root Tissue&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/xref&gt;
Authors: M LEVINE
Journal: JNCI Journal of the National Cancer Institute (1950)

The Growth of Normal Plant Tissue in vitro as Affected by Chemical Carcinogens and Plant Growth Substances. II. the Cytology of the Carrot-Root Tissue Get access Michael Levine Michael Levine Laboratory Division, Montefiore Hospital, New York, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 5, April 1950, Pages 1005–1041, https://doi.org/10.1093/jnci/10.5.1005 Published: 01 April 1950 Article history Received: 20 July 1949 Published: 01 April 1950
Target the message: a qualitative study exploring knowledge and cultural attitudes to sunlight and vitamin D in Greater Manchester, U.K.
Authors: A.R. Webb, S. Aseem, R.C. Kift, L.E. Rhodes, M.D. Farrar
Journal: British Journal of Dermatology (2016)

Vitamin D is vital for musculoskeletal health and has been associated with protection against several internal cancers and auto-immune diseases. Skin synthesis following exposure to ultraviolet radiation (UVR) in sunlight is the major source of the vitamin, with diet providing only small amounts. Skin synthesis requires sunlight exposure containing sufficient UVB to initiate vitamin D synthesis, which precludes the winter months at mid-high latitudes, including the UK.

This article is protected by copyright. All rights reserved.
CMS-06THE NOPHO-EUROPEAN STUDY ON CEREBELLAR MUTISM SYNDROME (CMS)
Authors: Morten Wibroe, Shivaram Avula, Johan Cappelen, Charlotte Castor, Niels Clausen, Irene Devenney, Greg Fellows, Pernilla Grillner, Ramneek Gupta, Bengt Gustavsson, Mats Heyman, Stefan Holm, Atte Karppinen, Rosita Kiudeliene, Camilla Klausen, Päivi Lähteenmäki, Tuula Lönnqvist, Stephen Lowis, Conor Mallucci, René Mathiasen, Mattias Mattson, Pelle Nilsson, Kristiina Nordfors, Per Nyman, Karsten Nysom, Karin Persson, Jouni Pesola, Barry Pizer, Olof Rask, Magnus Sabel, Kjeld Schmiegelow, Astrid Sehested, Ingrid Tonning-Olsson, Ingrid Kristin Torsvik, Kirsten van Baarsen, David Walker, Mia Westerholm-Ormio, Barbara Zetterqvist, Marianne Juhler
Journal: Neuro-Oncology (2016)
Anorexia nervosa
Authors: R. McKnight, N. Boughton
Journal: BMJ (2009)

<b>Objective:</b> The relationship between the posterior cortex and cognitive functions is still a relatively open field. There are no studies on populations in which functions of posterior structures were examined by a standardised neuropsychological examination before and after posterior resections. Changes in cognitive performance are regularly observed after epilepsy surgery in the temporal lobe. However, information about neuropsychological impairments after resections in the posterior cortex is poor, owing to the relatively low proportion of cortical resections in this area. <b>Methods:</b> We retrospectively studied changes in cognition in the neuropsychological data of 28 patients prior to and 6 months after posterior cortical resections. <b>Results:</b> Cognition significantly showed differences in performance intelligence quotient compared with verbal intelligence quotient. Post-operative verbal intelligence consistently increased, whereas performance intelligence decreased. There was no effect regarding the lesion side, continuation of seizures, or reduction of visual field after surgery. Epilepsy surgery in this area did not lead to significant differences in general intelligence after surgery. <b>Conclusion:</b> Functions of posterior areas could be described by standardised neuropsychological measures. Posterior regions contribute to explicit attentional and visuoconstructional abilities. Epilepsy surgery in the posterior cortex bears no risk for substantial decline in general cognition although some discrete impairment in performance intelligence may occur.
PCM-14DEVELOPMENT OF A NEW DIPG ORTHOTOPIC MODEL IN MICE USING AN IMPLANTABLE GUIDED-SCREW SYSTEM
Authors: Miguel Marigil, Naiara Martínez-Vélez, Pablo Dominguez, Miguel Angel Idoate, Oren J. Becher, Ricardo Díez-Valle, Sonia Tejada, Marta M. Alonso
Journal: Neuro-Oncology (2016)
Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin‐6 signaling in hepatocellular carcinoma
Authors: Carolin Ploeger, Nina Waldburger, Angelika Fraas, Benjamin Goeppert, Stefan Pusch, Kai Breuhahn, Xin Wei Wang, Peter Schirmacher, Stephanie Roessler
Journal: Hepatology (2016)

Several chronic inflammatory liver diseases, e.g., chronic hepatitis B or C viral infection and steatohepatitis, have been shown to predispose to the development of hepatocellular carcinoma (HCC). In patients with chronic liver disease, interleukin‐6 (IL‐6) serum levels are elevated and increase even more when HCC develops. However, the impact and regulatory mechanisms of IL‐6 signaling during hepatocarcinogenesis are still poorly defined. Here, we show that gene expression profiles of patients with chromosome 8p loss correlate with increased IL‐6 signaling. In addition, the chromosome 8p tumor suppressor genes Src homology 2 domain containing 4A (SH2D4A) and Sorbin and Src homology 3 domain containing 3 (SORBS3) together exerted greater inhibition of cell growth and clonogenicity compared to a single gene. Overexpression of SH2D4A and SORBS3 in HCC cells led to decreased IL‐6 target gene expression and reduced signal transducer and activator of transcription 3 (STAT3) signaling. In situ and in vitro coimmunoprecipitation assays revealed that SH2D4A directly interacts with STAT3, thereby retaining STAT3 in the cytoplasm and inhibiting STAT3 transcriptional activity. On the other hand, SORBS3 coactivated estrogen receptor α signaling, leading indirectly to repression of STAT3 signaling. In human HCC tissues, SH2D4A was positively associated with infiltrating regulatory and cytotoxic T‐cell populations, suggesting distinct immunophenotypes in HCC subgroups with chromosome 8p loss. Thus, the genetically linked tumor suppressors SH2D4A and SORBS3 functionally cooperate to inhibit STAT3 signaling in HCC. Conclusion: The chromosome 8p tumor suppressor genes SORBS3 and SH2D4A are physically and functionally linked and provide a molecular mechanism of inhibiting STAT3‐mediated IL‐6 signaling in HCC cells. (H epatology 2016;64:828‐842)
Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).
Authors: J. Lee, V. Hirsh, K. Park, S. Qin, C. R. Blajman, R. Perng, L. Emerson, P. B. Langmuir, C. Manegold
Journal: Journal of Clinical Oncology (2010)

7525 Background: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling. This study assessed whether vandetanib conferred an overall survival (OS) benefit vs placebo in patients (pts) with locally advanced or metastatic NSCLC after failure of prior therapy with an EGFR TKI. Methods: Eligible pts (stage IIIB/IV NSCLC; WHO PS 0–2; all histologies permitted; 1–2 prior chemotherapies; prior EGFR TKI) were randomized 2:1 to receive vandetanib 300 mg/day or placebo until progression/toxicity. The primary objective was to show superiority in OS (> 90% power to detect ≥ 25% reduction in death rate; hazard ratio [HR] ≤ 0.75). Secondary efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) at 8 weeks. Results: Between Nov 2006–Nov 2008, 924 pts (mean age 60 yrs; 53% female; 56% East Asian; 53% non-smoker; 79% adenocarcinoma; 58% 2 previous chemotherapy regimens) received vandetanib (n = 617) or placebo (n = 307). Baseline characteristics were similar in both arms. At data cut-off (Oct 09), median follow-up was 15.4 months with 90% pts progressed and 76% pts dead. There was no difference in OS for pts receiving vandetanib vs placebo (HR 0.95, 95.2% CI 0.81–1.11; p = 0.527); median OS was 8.5 months (vandetanib) and 7.8 months (placebo). Significant advantages favoring vandetanib were seen for the secondary endpoints of PFS (HR 0.63, 95.2% CI 0.54–0.74; p < 0.0001), ORR (2.6% vs 0.7%: p = 0.028) and DCR at 8 weeks (30% vs 16%; p < 0.0001). Post-progression therapy was balanced across the arms in both number and type. Adverse events (AEs) observed for vandetanib were generally consistent with previous NSCLC studies of vandetanib 300 mg. Common AEs (any grade) occurring with a greater frequency in the vandetanib arm included diarrhea (46% vs 11%), rash (42% vs 11%) and hypertension (26% vs 3%). Conclusions: The study did not meet its primary objective of demonstrating an OS benefit with vandetanib vs placebo in pts with advanced NSCLC who had previously failed chemotherapy and received treatment with an EGFR TKI, although PFS was better with vandetanib vs placebo. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, Roche AstraZeneca, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, Roche AstraZeneca
Early high-dose therapy and autologous stem-cell transplantation in angioimmunoblastic T-cell lymphoma: Outcome study using the National Cancer Data Base.
Authors: Pawan Kumar Karanam, Benjamin Marshall Parsons, Mohammed Al-Hamadani, Ronald S. Go
Journal: Journal of Clinical Oncology (2015)

8560 Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare aggressive non-Hodgkin lymphoma with a poor outcome. The role of high-dose therapy followed by autologous stem-cell transplantation as a consolidation strategy (early SCT) remains undefined. We studied the outcome of AITL patients who received early SCT using the National Cancer Data Base (NCDB). Methods: Patient level data were obtained from the NCDB Participant User File. The NCDB collects hospital cancer registry data representing 70% of newly diagnosed cancer cases in the US population. We identified AITL patients (ICD-O: 9705) diagnosed in 1998-2011 for demographics, disease and treatment characteristics. We included patients diagnosed from 1998-2006 in the overall survival (OS) analyses. Patients who received SCT as part of their first course of treatment were considered to have early SCT. Results: From 1998-2011, 515,026 patients were diagnosed with NHL and 3,160 (0.6%) had AITL. The median age at diagnosis was 69 years (range, 18-90+) and 52.8 % were males. The stage distribution was as follows: I (5.8 %), II (6.7%), III (35.4%), IV (34.8%), and unknown (17.3%). The median overall survival (OS) for the entire cohort was 17.7 months. Compared to those diagnosed in 1998-2000, patients diagnosed in 2001-2003 (HR: 1.09; 95% CI: 0.94-1.28) and 2004-2006 (HR: 0.99; 0.86-1.16) had similar OS. There were 201 patients (6.4%) who received early SCT. The use of early SCT steadily increased over time from 1.0% in 1998 to 9.5% in 2011 (P < 0.001). The unadjusted OS was superior among patients who had early SCT (median 94.8 versus 16.7 months; HR: 2.46; 1.68-3.60). On multivariable analysis, age > 70 years (HR: 1.65; 1.40-1.95), Black race (HR: 1.35; 1.10-1.67), stage III/IV (HR 1.24; 1.04-1.50) and not having early SCT (HR 1.89; 1.28-2.79) were associated with inferior OS. Conclusions: This is the largest series of AITL reported to date. The OS remains poor and has not improved during the study period. The use of early SCT has increased ten-fold in the past decade. Early SCT may improve long term outcome and warrants further evaluation.
Concentration of Quinine in Gastrointestinal Cancers (Preliminary Report)&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: F. E. Kelsey, A. Brunschwig
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article Concentration of Quinine in Gastrointestinal Cancers (Preliminary Report) Get access F. E. Kelsey, F. E. Kelsey Departments of Pharmacology and Surgery, The University of Chicago Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Brunschwig A. Brunschwig Departments of Pharmacology and Surgery, The University of Chicago Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 5, April 1947, Pages 355–356, https://doi.org/10.1093/jnci/7.5.355 Published: 01 April 1947
MB-24ROUTINE DIAGNOSTIC MEDULLOBLASTOMA SUBGROUPING USING LOW-COST, LOW-INPUT DNA METHYLOMICS: APPLICATION TO TRIALS COHORTS PREVIOUSLY REFRACTORY-TO-ANALYSIS
Authors: Edward Schwalbe, Debbie Hicks, Gholamreza Rafiee, Matthew Bashton, Henning Gohlke, Amir Enshaei, Sandeep Potluri, Jessie Matthiesen, Michael Mather, Pim Taleongpong, Ria Chaston, Steve Crosier, Amanda Smith, Franck Bordeaut, Francois Doz, Stefan Rutkowski, Birgitta Lannering, Simon Bailey, Torsten Pietsch, Daniel Williamson, Steven Clifford
Journal: Neuro-Oncology (2016)
P-208 The Therapeutic Effect of Irreversible Electroporation Ablation in Colon Cancer Animal Model
Authors: H.S. Choi, H.J. Chun, I.K. Yoo, J.M. Lee, S.H. Kim, E.S. Kim, B. Keum, Y.T. Jeen, H.S. Lee, C.D. Kim
Journal: Annals of Oncology (2015)
TB-17A COMPREHENSIVE PAN-CANCER ANALYSIS OF CHILDHOOD MALIGNANCIES
Authors: Susanne N. Groebner, Barbara Worst, David T.W. Jones, Ivo Buchhalter, Kortine Kleinheinz, Joachim Weischenfeldt, Pascal D. Johann, Maia Segura-Wang, Paul A. Northcott, Marcel Kool, Barbara Hutter, Sebastian Bender, Jan O. Korbel, Matthias Schlesner, Lukas Chavez, Marc Zapatka, Peter Lichter, Stefan M. Pfister
Journal: Neuro-Oncology (2016)
Percutaneous Transluminal Angioplasty
Authors: S Nemoto
Journal: Annals of Internal Medicine (1983)

Percutaneous transluminal angioplasty is a relatively new procedure; its technology is still evolving and experience with it is increasing rapidly. There are only limited follow-up data on patients who have undergone this technique. Rates of late patency of the dilated arteries and potential long-term complications in patients treated with percutaneous transluminal angioplasty are unknown. Therefore, physicians performing this technique should collect and report long-term follow-up data on their patients, using clinical, hemodynamic, and angiographic determinations. Physicians evaluating the literature must recognize the substantial impact that physician experience, patient selection, and measures of clinical success have on reported results. Before sending a patient for angioplasty, one should consider the experience of the center where the procedure will be done. In making comparisons between treatments and techniques, one must be sure that comparable populations are studied and that angiographic, clinical, and hemodynamic variables are measured in all patients, because patients may show improvements in some variables but not others. The availability of improved balloon-tipped catheters, more potent vasodilators, and enhanced experience and skill may bring about improved results from percutaneous transluminal angioplasty in the future. Moreover, advances in diagnostic technology, such as the refinement of digital subtraction angiography, may alter the approach to patients with vascular disease, facilitating the identification of potential candidates at lower risk for this technique more efficiently. As new data emerge, particularly information dealing with the duration of therapeutic effect and the occurrence of late complications, continued reevaluation of the procedure will be necessary. Coronary percutaneous transluminal angioplasty is an alternative to coronary artery bypass graft surgery in patients with high grade stenosis (greater than 50% to 70%) confined to a single coronary artery and limiting anginal symptoms despite an adequate trial of medical treatment. The success of percutaneous transluminal angioplasty of a proximal left anterior descending artery lesion approaches that of coronary artery bypass graft surgery. Percutaneous transluminal angioplasty of other coronary artery lesions is somewhat less successful than that of coronary artery bypass graft surgery. Percutaneous transluminal angioplasty of multiple coronary arterial lesions remains investigational.
Private practice of psychiatry: future roles
Authors: Z M Lebensohn
Journal: American Journal of Psychiatry (1978)

Psychiatrists in private practice have contributed more to treating the mentally ill in America than is generally known. The private practice sector may be viewed as a massive national outpatient and inpatient service for the mentally ill. The impact of national health insurance on the future character of the private practice of psychiatry and the thorny problems to be resolved are discussed and compared with the experiences of England, the Soviet Union, and China. Future trends will most likely include increased emphasis on adjuvant techniques, greater emphasis on resident training in general psychiatry, briefer forms of therapy, and psychiatry's return to the medical model.